Lupin Ltd.

Financial

	Lupin	Zydus Lifesciences	Mankind Pharma
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	442.0 .	486.0 .	67.0 .
Number of ANDA's Approved By USFDA	342.0 .	421.0 .	48.0 .
Domestic Sales Growth - YoY	7.0 %	6.7 %	7.9 %
US DMF Filings	92.0 .	147.0 .	n/a
R&D as a % of Total Sales	7.9 %	8.1 %	2.2 %
Financials
5 yr Average ROE	6.43 %	18.47 %	20.33 %
5yr average Equity Multiplier	1.73	1.52	1.46
5yr Average Asset Turnover Ratio	0.75	0.66	0.81
5yr Avg Net Profit Margin	5.06 %	19.02 %	17.68 %
Price to Book	5.2	4.15	7.12
P/E	24.2	21.76	53.91
5yr Avg Cash Conversion Cycle	-84.38 Days	-84.89 Days	-13.08 Days
Inventory Days	53.29 Days	36.38 Days	59.06 Days
Days Receivable	50.0 Days	36.93 Days	34.35 Days
Days Payable	160.27 Days	160.15 Days	121.69 Days
5yr Average Interest Coverage Ratio	6.26	30.19	46.07
5yr Avg ROCE	10.02 %	19.65 %	25.06 %
5yr Avg Operating Profit Margin	14.15 %	24.4 %	24.62 %
5 yr average Debt to Equity	0.3	0.17	0.16
5yr CAGR Net Profit	21.95 %	16.23 %	9.49 %
5yr Average Return on Assets	3.91 %	12.22 %	14.46 %
Shareholdings
Promoter Holding	46.9 %	74.99 %	72.68 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-0.2 %	0.11 %	-3.82 %
Change in Mutual Fund Holding (3 Yrs)	3.49 %	0.94 %	5.51 %

Business

	Lupin	Zydus Lifesciences	Mankind Pharma
Product Wise Break-Up	Product Wise Break-Up Advanced Markets Formulations 45.0 India 34.0 Emerging Market 12.0 Active Pharmaceutical Ingredient (API) 9.0 NCD 1.0 USA 0 Developed Markets 0 Generic FDF 0 Custom Synthesis 0 IM Formulations 0 Emerging Markets 0 Europe Formulatios 0 Alliances 0 Wellness 0 Animal Health 0 India Formulations 0 US Formulations 0 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0	Product Wise Break-Up Dermatology 0 Europe Formulatios 0 Wellness 13.86 India 0 Anti-infectives 0 Active Pharmaceutical Ingredient (API) 0 India Formulations 24.75 Alliance 0.45 VMN 0 Emerging Market 0 EMB Formulations 8.91 USA 0 Custom Synthesis 0 Advanced Markets Formulations 0 Neuro/CNS 0 NCD 0 Emerging Markets 0 Gastro - Intestinal 0 Anti-Diabetic 0 US Formulations 49.5 Urology 0 Pain/Analgesics 0 Cardiovascular 0 Respiratory 0 Generic FDF 0 Animal Health 0 Gynaecology 0 Developed Markets 0 Others 2.53	Product Wise Break-Up Dermatology 5.0 Europe Formulatios 0 Wellness 0 India 0 Anti-infectives 16.0 Active Pharmaceutical Ingredient (API) 0 India Formulations 0 Alliances 0 VMN 9.0 Emerging Market 0 IM Formulations 0 USA 0 Custom Synthesis 0 Advanced Markets Formulations 0 Neuro/CNS 4.0 NCD 0 Emerging Markets 0 Gastrointestinal 11.0 Anti-Diabetic 9.0 US Formulations 0 Urology 5.0 Pain/Analgesics 5.0 Cardiovascular 12.0 Respiratory 6.0 Generic FDF 0 Animal Health 0 Gynaecology 11.0 Developed Markets 0 Others 7.0
Segment Break-Up	Segment Break-Up Pharmaceuticals 99.49 Research Services & Sale of IP`s 0 Consumer Products 0 Others 0.51	Segment Break-Up Research Services & Sale of IP`s 0 Pharmaceuticals 86.05 OTC 13.95	-
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Cardiac Science 23.0 Anti - Diabetes 21.0 Respiratory Systems 14.0 Gastro Intestinal 10.0 Anti-Infective 7.0 Central Nervous System (CNS) 5.0 Gynecology 4.0 Pain Management 3.0 Anti-Tuberculosis 3.0 Vitamins / Minerals / Nutrients 3.0 Others 7.0	-	-
Location Wise Break-Up	Location Wise Break-Up USA 39.0 India 34.0 Developed Markets 13.0 EMEA 10.0 API 4.0 Japan 0 Nepal 0 Sri Lanka 0 Bangladesh 0	Location Wise Break-Up Nepal 0 India 39.81 USA 47.94 Japan 0 API 0 Sri Lanka 0 Bangladesh 0 Developed Markets 0 EMEA 0 Others 12.25	Location Wise Break-Up Nepal 0 India 87.0 USA 0 Japan 0 API 0 Sri Lanka 0 Bangladesh 0 Developed Markets 0 EMEA 0 Others 13.0
Acute vs Chronic	Acute vs Chronic Chronic 63.1 Acute 36.9	-	Acute vs Chronic Chronic 38.8 Acute 61.2

Lupin Ltd.

SIGN UP FOR FREE